Ainos (NASDAQ:AIMD) Issues Quarterly Earnings Results

Ainos (NASDAQ:AIMD) announced its earnings results on Wednesday. The company reported ($0.41) earnings per share (EPS) for the quarter, Zacks reports. Ainos had a negative return on equity of 144.01% and a negative net margin of 11,912.10%.

Ainos Trading Up 1.8%

Shares of AIMD opened at $1.74 on Friday. Ainos has a 52-week low of $1.26 and a 52-week high of $4.50. The company has a quick ratio of 0.78, a current ratio of 1.06 and a debt-to-equity ratio of 1.45. The firm’s fifty day moving average is $1.60 and its two-hundred day moving average is $1.92. The stock has a market cap of $12.65 million, a PE ratio of -0.60 and a beta of 2.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AIMD. Two Sigma Investments LP acquired a new position in shares of Ainos during the 3rd quarter valued at about $80,000. Renaissance Technologies LLC boosted its position in shares of Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after acquiring an additional 7,700 shares during the last quarter. DRW Securities LLC boosted its position in shares of Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after acquiring an additional 48,439 shares during the last quarter. Finally, Mariner LLC acquired a new position in shares of Ainos during the 4th quarter valued at about $37,000.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ainos in a research note on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Ainos presently has a consensus rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.